The MoU aims to strengthen cooperation in the prevention, diagnosis, and treatment of these two urgent health challenges in Vietnam. It underscores Johnson & Johnson’s commitment to applying innovative medical solutions to enhance the quality of life for patients across the country.

The collaboration will focus on optimizing treatment protocols, improving patient experiences, and delivering better outcomes. Key areas of cooperation include raising awareness and diagnosis of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC), expanding the use of next-generation sequencing (NGS), strengthening medical training and knowledge exchange, and building capacity for healthcare professionals. The partnership will also promote multidisciplinary collaboration, bringing together doctors from various specialties to deliver comprehensive care.

The MoU aims to strengthen cooperation in the prevention, diagnosis, and treatment of these two urgent health challenges in Vietnam. Photo courtesy of Johnson & Johnson

Upendra Patkie, General Director of Johnson & Johnson Vietnam, emphasized the company’s patient-centered approach. “Recognizing the urgent needs of those living with lung and prostate cancer – two of the most prevalent and life-altering diseases in Vietnam, we are committed to delivering innovative treatments that not only extend life but also improve its quality. Through our MOU with HCMC Oncology Hospital, we are proud to unlock access to these breakthrough therapies, helping more patients receive the care they need.”

Cancer continues to pose a major health burden in Vietnam. According to GLOBOCAN data, lung cancer was the third most common cancer in 2022, with over 24,000 new diagnoses. It was also the second leading cause of cancer- deaths, claiming more than 22,000 lives annually. About three-quarters of lung cancer cases are diagnosed at a late stage, when treatment options are limited and survival rates are low. Non-small cell lung cancer accounts for approximately 80-85% of all lung cancer cases.

Prostate cancer is also on the rise among Vietnamese men. In 2022, nearly 5,900 new cases were recorded, making it one of the five most common cancers among men and accounting for about 2.3% of cancer deaths.

Johnson & Johnson believes that health is the foundation of everything good in life. The company is working to create a world where complex diseases can be prevented and cured, treatments are smarter and less invasive, and healthcare solutions are increasingly personalized.